




Life Sciences

in the Berlin-Brandenburg Capital Region

THE GERMAN CAPITAL REGION
MORE VALUE FOR YOUR INVESTMENT



- 1 The Berlin-Brandenburg Life Sciences Region
- 2|3 Research Location
- 4|5 Oncology
- 6|7 Cardiovascular Disease
- 8|9 Diagnostics
- 10|11 Implants, Biomaterials & Regenerative Medicine
- 12|13 Life Sciences Map
- 14|15 Linking Science & Business
- 16|17 Pharmaceutical Industry
- 18|19 Clinical Research, Hospitals & Health Care
- 20|21 Manufacturing & Production
- 22|23 Strategic Advantages
- 24 A Great Place to Live
- Contacts | Imprint



Advantages of the Life Sciences Region Berlin-Brandenburg

- Unique concentration and excellence of internationally renowned research institutes
- Charité – one of the world’s largest university hospitals
- Outstanding infrastructure
- Synergies via well-established networks
- Sustainable technology clusters

- Highly qualified workforce
- Low labor costs and flexible working hours
- Excellent conditions for production
- Political support – Master Plan
- Best funding support in the EU

- Attractive capital city region
- High quality of life
- Low cost of living
- Affordable and available real estate
- Political decision-making center

450

biotech and medtech companies

30

pharmaceutical companies

37

universities and technical colleges

170,000

university-level students

A workforce of **350,000**

in the health care industry




The Brandenburg Gate in the center of Berlin lit up at night

Europe's Leading Life Sciences Region

Major strategic advantages in Berlin-Brandenburg

Berlin-Brandenburg is one of the leading locations in Europe for the life sciences. This high-performance region at the very heart of Europe outshines its international competitors with clear strategic advantages: Berlin-Brandenburg has a unique scientific environment, and its strategic linkage of science, clinical research, health care and business leads to maximum research output and quick conversion into innovative products. This effective process is made possible by the presence of one of the largest teaching hospitals worldwide, Charité University Medicine Berlin, as well as 480 life sciences companies and over 100 non-university research institutes. The political sphere also gives significant support to the ongoing development of key factors for success, such as the region's highly qualified workforce – the region has an above-average

pool of experts who are highly educated, multilingual and multicultural – as well as its outstanding infrastructure, the availability of low-cost office and commercial space and the fostering of ideal basic conditions. At the same time, the captivating German capital region also magnetically attracts internationally renowned scientists and experienced managers from all over the world. No other region offers such a brilliant range of diversity combined with a high standard – yet low cost – of living. Additionally, in October 2011, the region will become even more accessible with the opening of the Berlin-Brandenburg International Airport (BBI). As Europe's most modern airport, BBI will take travelers to and from 160 destinations in 50 countries across the world.



Research lab at Bayer Schering Pharma

Europe's Leading Research Location

Science as the driving force behind value creation

Over the past several years, Berlin-Brandenburg has emerged as the most important location for scientific research in Europe. Nowhere else can you find such a high density and superior quality of research institutes. Distinct synergies result from intensive collaboration among the life sciences as well as the integration of key technologies from other disciplines, such as information technology, nanotechnology, optics and microsystems engineering. Expenditures on research and development in Berlin are equal to almost 4 percent of the state's gross domestic

product and, as such, they lie far above Germany's national average. The Berlin-Brandenburg region's unique concentration and linkage of research, hospitals, clinics and business not only leads to maximum performance in research, but also to the successful conversion of that research into innovative products. Roughly 450 regional companies in the fields of biotechnology and medical technology are involved in this unique process. For a detailed overview of Berlin's vast scientific landscape, please visit www.berlin-sciences.com.

Leading International Research Location

Universities and technical colleges	37
More than 100 non-university research institutes, including:	
Institutes of the Max Planck Society	8
Institutes of the Hermann von Helmholtz Association	7
Institutes of the Leibniz Association	22
Branch Institutes of the Leibniz Association	6
Institutes of the Fraunhofer Society	9

Efficient Technology Transfer

Successful spin-off companies emerging from universities and research institutes

- | | |
|---|---|
| <ul style="list-style-type: none"> • Analyticon Discovery • Berlin Heart • Biotronik • Celon (Olympus Medical Group) • Eckert & Ziegler • Epigenomics • InnoRa | <ul style="list-style-type: none"> • Jerini • JPK Instruments • MagForce • MerLion Pharma • metanomics • Mologen • Noxxon • Organobalance • Scienion |
|---|---|

Berlin-Brandenburg – Science-based Industry as a Key Economic Factor

Professor Stock, what characterizes Berlin-Brandenburg as a research location?

Berlin has been setting global standards in science ever since the age of Nobel Prize winners such as Emil von Behring, Robert Koch, Max Planck and Albert Einstein. We have an unusually high concentration of excellent research institutes, which allows us to assume a leading position in Europe. The potential here is enormous, especially with top research facilities such as the Max Planck institutes, Helmholtz institutes and Fraunhofer institutes as well as the major universities and technical colleges. Over 85,000 people work here in science and research. Evidence of the region's outstanding international reputation is found in its ongoing ability to attract foreign students and young scientists. In fact, approximately 25,000 of the region's 170,000 university-level students come from abroad.

“Berlin-Brandenburg has all the elements of the value chain in the field of biomedicine. This distinguishes the region from all other locations.”

What role do science and research play in the Berlin-Brandenburg economy?

Research and science are the capital region's major strengths. We place uncompromising emphasis on support for science-based industries. Projects initiated in the 1990s have already started bearing fruit. Some of the region's most notable success stories involve innovative industrial products developed in the fields of biotechnology and medical technology. Berlin-Brandenburg has all the elements of the value chain in the field of biomedicine, ranging from basic research all the way to young, technology-oriented companies and major manufacturers. This distinguishes the region from all other locations.



Prof. Dr. Dr. h.c. Günter Stock
Master Plan Coordinator and Network Spokesman
HealthCapital Berlin-Brandenburg
www.healthcapital.de

How would you rate the political support provided in this field?

Politicians realized the field's potential early on and acted quickly and decisively. A “master plan” initiated by the states of Berlin and Brandenburg – entitled “Berlin-Brandenburg Health Care Region” – unites the commitments of the two states to the goal of using the region's unique potential as effectively as possible. The “HealthCapital Berlin-Brandenburg” brand was created by the Health Care Industry Network as part of the master plan.

What role does “HealthCapital” play in this scenario?


All activities that foster the strengths of the region's health care cluster are integrated and coordinated under the HealthCapital umbrella brand. Members of our network include important players from all of the health care branches that make the region so successful, such as universities and other educational institutions, research institutes, companies active in the fields of pharmaceuticals, biotechnology and medical technology, hospital operators, health insurers, service providers and funding institutions.

What role does culture play in the Berlin-Brandenburg scientific community?

The great metropolitan cities of the world are all known for their ability to create and sustain a reasonable symbiosis between politics, culture, science and industry. For many scientists, culture is a special source of inspiration. Berlin fulfills this criterion in an exemplary manner.



From left to right
New offices of the Fraunhofer Institute for Biomedical Engineering (IBMT) in the Potsdam-Golm Science Park
Metabolite profiling at Metanomics in Berlin-Charlottenburg
Max Delbrück Communications Center in Berlin-Buch



Implantation of Eckert & Ziegler low-level radioactive iodine seeds in the prostate

A Leading Position in Oncology

Sophisticated research, ground-breaking diagnostic technologies, innovative therapies

Facilities in the Berlin-Brandenburg region regularly achieve groundbreaking results in the fight against cancer. Charité, the Max Delbrück Center for Molecular Medicine (MDC) and the Max Planck Institute for Molecular Genetics (MPI-MG) are only three examples of the region's outstanding expertise. Twenty-one research groups are active in the MDC's research program alone.

The MPI-MG coordinates a cancer-oriented European network for systems biology (ESBIC-D). A number of life science companies are working on developing new diagnostic and therapy concepts. Bayer Schering Pharma is reporting significant growth rates in cancer medications and also features an extensive development pipeline.

Leading Cancer Research

- Charité Comprehensive Cancer Center
- Cancer Network in the National Genome Research Network, Charité
- Competence Network Pediatric Oncology and Hematology (KPOH), Charité
- European Prospective Investigation into Cancer and Nutrition (EPIC) Study, German Institute for Human Nutrition
- UICC Telepathology Consultation Center at Charité Hospital

Product innovations from Berlin-Brandenburg in the field of cancer diagnostics and therapies

- Innovative cancer diagnostics using DNA methylation from Epigenomics
- Biochips for cancer diagnostics from Scienion, Invitek and Signature Diagnostics
- Gamma sensors and cameras for the detection and localization of lymph node metastases from Crystal Photonics and W.O.M.
- Innovative cancer medications from Bayer Schering Pharma
- Systematic RNAi therapies from Silence Therapeutics
- Cancer immunity therapies from Mologen
- Human and glyco-optimized antibodies and other bio therapies from Glycotope
- Thermotherapy processes using magnetic nano-particles from MagForce and thermotherapy processes using radio frequencies from Celon (Olympus Medical Group)
- Proton therapy at the Helmholtz Center Berlin for Materials and Energy
- Lasers for the treatment of tumors from Limmer Laser

Oncology is Pfizer's Top Priority

“Berlin and the entire capital region have emerged as Germany's most important center for medicine and the health care industries.”

German headquarters in Berlin since 2008

In 2008, Pfizer, the world's leading pharmaceutical company, moved its German headquarters to Potsdamer Platz in the heart of Berlin. Roughly 500 employees are now active here in the fields of medicine, clinical research, personnel, communications and marketing. “Berlin and the entire capital region have emerged as Germany's most important center for medicine and the health care industries,” says Dr. Andreas Penk, Country Manager for Pfizer Germany when asked why the global player chose Berlin. “We want to do our part to expand this position even further. Berlin has the potential to become the most important health care city in Europe and also to play a leading role worldwide.”

Using different therapeutic approaches to fight cancer effectively

As the world's leading producer of pharmaceutical products, Pfizer's goal is to improve the health and quality of life of both humans and animals. The company offers a wide range of innovative products for a number of illnesses. One of its major focuses is on the treatment of cancers. Pfizer invests over 20 percent of its research budget in oncology. In this field, the company currently boasts one of the most comprehensive portfolios of experimental substances and has 22 active agents in clinical development. Berlin has established itself as an excellent location for conducting clinical studies. “Nowhere else in Germany are there as many study centers participating in our cancer studies as there are in Berlin,” notes Penk. “This applies to all the tumors for which we are currently developing therapies.”


The importance of Pfizer's location in the German capital is also reflected in the fact that the company's European oncology business is managed from Berlin. As president of Pfizer Oncology Europe, Dr. Penk is responsible for this area as well.

Pfizer appreciates the many opportunities it enjoys to collaborate with the region's institutes not only in the field of oncology: “We're here to cooperate more closely with all decision-makers in the health care field. The region offers a number of first-class opportunities for collaboration, including hospitals and clinics, such as those operated by Charité, Vivantes and Helios, research institutes, universities and biotech companies. Right now, we're in the process of establishing and further expanding these cooperative efforts.”



Dr. Andreas Penk
Country Manager for Pfizer Germany
and President of Pfizer Oncology Europe
www.pfizer.de

“Nowhere else in Germany are there as many study centers participating in our cancer studies as there are in Berlin.”




From left to right

Iodine seeds from Eckert & Ziegler in Berlin-Buch are delivered in radiation-safe containers

Celon, a subsidiary of Olympus, in Teltow

Precise imaging of the bone metastases of a tumor in a mouse using a specific ¹⁸F-labeled PET tracer at Bayer Schering Pharma



Stent production at Biotronik

Innovative Treatment of Cardiovascular Diseases

Research findings flow directly into practical applications

As a result of its excellent basic research, translational medicine and first-class clinical care, Berlin has established itself as an internationally prominent center in the fields of cardiovascular and circulatory disease. Its outstanding reputation is based first and foremost on the work of the German Heart Institute Berlin (DHZB) and Charité. The DHZB and its offshoot, Berlin Heart, are international leaders in developing artificial hearts. Biotronik is among the leaders in the development of cardiac implants, and roughly 50 percent of the sales of Berlin-Chemie de-

rive from cardiovascular medications. Regional medical-technology companies profit from collaborative efforts with clinical institutes. Work is also being done in the application of telemedicine with the goal of providing patients with blanket coverage. Cardiovascular research will receive a further boost from the creation of the National Network for Cardiovascular Diseases (NNKE) and the foundation of the National Institute for Cardiovascular Diseases (NIKE) at the Max Delbrück Center.

German Heart Institute Berlin

Open heart surgeries (total since 1960)	61,700
Open heart surgeries (annual)	3,000
Hybrid operations (aorta, heart valves, congenital heart disease), total	1,400
Open heart surgery for newborns, infants, children (annual)	550
Heart transplants, 160 performed on children (total)	1,630
Heart and lung transplants (total)	460
Artificial heart implants (total)	1,330

Leading in Health Care and Research

- German Heart Institute Berlin
- Charité – University Medicine Berlin: Center for Heart, Circulatory and Vascular Medicine, Charité Center for Cardiovascular Research, coordination of the Heart Failure Competence Network, participation in the Cardiovascular Network of the National Genome Research Network
- Max Delbrück Center, including coordination of the research fields of cardiovascular and circulatory diseases of the Helmholtz Association
- Brandenburg Heart Center at the Evangelisch-Freikirchliche Hospital in Bernau
- Sana Heart Center in Cottbus

Berlin-Brandenburg – A Motor for Cardiological Innovation

Wide-ranging expertise

The entire life science community in the capital region boasts extensive and complementary expertise in the field of cardiovascular medicine, including research, clinical applications and product innovation. As a result, heart patients from all over the world choose to undergo treatment in Berlin, and high-quality products made in Berlin-Brandenburg also continue to be in high demand across the world. The region's leaders in the field of cardiovascular research include such institutions as the German Heart Institute Berlin, Charité – University Medicine Berlin and the Max Delbrück Center for Molecular Medicine (MDC). The MDC is home to the "Cardiovascular, Circulatory and Metabolic Diseases" program, which forms part of the Helmholtz Society's health care research activities. The integrative and interdisciplinary approach taken by the Center for Cardiovascular Research (CCR) at the Charité is unique in the field of cardiovascular research in Germany. Here, 12 working groups with a combined staff of over 100 individuals drawn from various disciplines collaborate on various projects. Two offshoots of Charité – Autotissue and Vasotissue – are at the cutting-edge in the field of cardiovascular tissue engineering and develop individual implants, such as heart valves and vascular prostheses using human cells.

"The keys to our success are all found in Berlin. They include a concentrated network of first-class clinics and prominent research institutes."

Global market leaders – cardiological medtech products from Berlin-Brandenburg

Approximately one-half of the sales generated by Berlin's internationally successful medical engineering companies involves implants and prostheses. Products from the



Christoph Böhmer
Managing Director, Biotronik GmbH & Co. KG
www.biotronik.com

"Berlin is an inspiring work environment for our employees."

field of cardiovascular systems account for 84 percent of the products in this group. Pacemakers, heart support systems, defibrillators and stents – high-quality products from Berlin-Brandenburg are very much in demand around the world. The most successful company in the field is Biotronik, a global leader in the production of cardiological implants. Whether it involves producing the first German pacemaker or the pioneering development of its Home Monitoring System, this successful 40 year-old company's trademark is constant innovation. Today, Biotronik employs a global workforce of over 4,500, of which 1,500 are active at the company's headquarters in Berlin-Neukölln. "The keys to our success are all found in Berlin," explains managing director, Christoph Böhmer. "They include a concentrated network of first-class clinics and prominent research institutes. Access to this know-how is just one of many important advantages provided by our location. Berlin also offers our employees an inspiring work environment. These basic conditions make it easy for us to find employees who have the key qualifications we need to support our ongoing growth."



From left to right
The INCOR® implantable cardiac support system from Berlin Heart in Berlin
Biomarker development for chronic heart failure at BRAHMS in Hennigsdorf
SeQuent PTCA® balloon catheter from B. Braun Melsungen in Berlin



Open high-field magnetic resonance imaging scanners allow for synchronized diagnostics and treatment

Optimally Positioned for Success

Early and precise diagnosis to benefit patients

Berlin-Brandenburg enjoys extraordinarily wide-ranging expertise in the field of bioanalytics, in-vitro diagnostics and in-vivo diagnostics. The region's tremendous potential is reflected in several companies. For example, Bayer Schering Pharma is the global leader in contrast media, BRAHMS enjoys a leading position in thyroid and sepsis diagnostics, and Epigenomics produces innovative cancer diagnostics based on DNA methylation. The region also offers ultra-modern facilities equipped with the latest in cutting-edge technology for diagnostic imaging. Some outstanding examples include one of the world's first open

high-field magnetic resonance tomography scanners at the Charité, a 7 Tesla MRI at the Max Delbrück Center as part of the Experimental and Clinical Research Center (ECRC) and the high-tech equipment at the Imaging Science Institute (ISI), a joint venture of Siemens and the Charité hospital that serves as an interface between research and clinical practice. The upcoming Center for Molecular Diagnostics and Bioanalytics currently under construction will soon form the very heart of developments in innovative diagnostics.

Leading in Diagnostics and Bioanalytics

- A. Menarini Diagnostics
- Attomol
- Bayer Schering Pharma
- BRAHMS
- BST Bio Sensor Technology
- CellTrend
- Charité – University Medicine Berlin
- CONGEN
- German Heart Institute Berlin
- Epigenomics
- Fraunhofer Institute for Biomedical Engineering
- GA Generic Assays
- Imaging Science Institute
- In.vent DIAGNOSTICA
- Invitek
- LIMETEC Biotechnologies

Distinct Network Structures

- Max Delbrück Center for Molecular Medicine
- Metanomics Health
- MicroDiscovery
- National Metrology Institute for Scientific and Technical Services (PTB)
- Scienion
- Signature Diagnostics
- Berlin NeuroImaging Center (BNIC)
- DiagnostikNet Berlin-Brandenburg
- Imaging Network Berlin (INB)
- Center for Molecular Diagnostics and Bioanalytics (ZMDB)

BRAHMS Diagnostics – A Market Leader from Brandenburg

Providing the world with high-quality products from Hennigsdorf

Since its founding in 1994, BRAHMS has always blazed a trail of its own. It was the first company in the pharmaceutical industry to emerge from a management buyout. Even today, almost all of the founding members that took over the diagnostics company from Henning Berlin/Marion Merrell Dow are still on the executive team. After five years, the fast-growing company moved to its current location at the newly founded Hennigsdorf Biotech Center.



Dr. Bernd Wegener
CEO BRAHMS AG
www.brahms.de

“In Hennigsdorf, we enjoy an optimal infrastructure for our business. We also profit immensely from close contacts with the park management and local authorities.”

“In Hennigsdorf, we enjoy an optimal infrastructure for our business. We also profit immensely from close contacts with the park management and local authorities,” explains Dr. Bernd Wegener, CEO of BRAHMS AG and chairman of the German Pharmaceutical Manufacturers Association (BPI). “The significant political support we receive also facilitates our work.” Today, the internationally successful company has a total of approximately 400 employees, 220 of which work at its headquarters in Hennigsdorf. The company’s range of products includes more than 60 innovative in-vitro diagnostic and lab-analysis systems designed for conducting immunoassays.

“We take advantage of the region’s outstanding expertise by cooperating with the Max Planck Institute for Infection Biology, the University of Potsdam and the Charité hospital.”

BRAHMS diagnostics smooth the progress of therapy decisions

On the basis of its strong position in the field of thyroid diagnostics, BRAHMS was also able to achieve a leading position in the fields of sepsis diagnostics. The company is also active in the fields of cardiovascular diseases, tumor diseases, fertility and prenatal diagnostics. Basic research and the exploration of new biomarkers play a central role. One-to-two patents are registered every month. BRAHMS has developed the world’s first test with which a sepsis – the most common cause of death in intensive care units – can be detected within one hour. The test for the biomarker Procalcitonin (PCT) provides rapid and reliable information as to whether a bacterial or viral infection is present, which is an important criterion in choosing the appropriate treatment. “Inflammatory and autoimmune diseases are fields of central importance,” explains Wegener. “We take advantage of the region’s outstanding expertise by cooperating regularly with the Max Planck Institute for Infection Biology, collaborating with the University of Potsdam for the development of measuring systems, and working with the Charité hospital for the clinical validation of our tests.” BRAHMS recently introduced ultra-sensitive tests for use in hospital emergency wards. These tests are designed to provide absolute clarity as to whether a heart or lung infection is present and also to determine a patient’s prognosis.



From left to right

Early detection of colon and lung cancer in the blood, developed by Epigenomics, Berlin

Bayer Schering Pharma and the Imaging Science Institute collaborate in the field of contrast-enhanced imaging

BRAHMS headquarters in Hennigsdorf



Flexible lens developed by Acri.Tec, a company belonging to Carl Zeiss Meditech in Hennigsdorf

Innovative Products for a Growing Market

Bringing together regional technologies and expertise

Berlin-Brandenburg stands for high-quality implants, including Berlin Heart's artificial hearts and Biotronik's pacemakers, as well as for solutions in the field of muscular-skeletal disease at companies such as aap, Biomet and Merete and for outstanding product development in tissue engineering. Examples include the award-winning heart valves from Autotissue and Codon's transplants of cartilage from the patient's own body. At the GKSS's Center of Biomaterial Development, research focuses on developing innovative polymer-based biomaterials. Scientific research, hospitals and clinics, and manufac-

turing companies are linked to one another at the highest levels. Implants, innovative biomaterials and regenerative therapies fostering self-healing are increasing in importance, particularly as a result of demographic developments. These areas are also interacting more and more. For example, the Berlin-Brandenburg Center for Regenerative Therapies (BCRT), a research center for translational medicine at the Charité hospital that works in cooperation with the Helmholtz Association, brings together expertise in the field of regenerative medicine.

Leading Research Institutes

- Berlin-Brandenburg Center for Regenerative Therapies (BCRT)
- Federal Institute for Materials Research and Testing (BAM)
- Charité – University Medicine Berlin
- Muscular-skeletal Research Center Berlin at the Charité
- Fraunhofer Institute for Applied Polymer Research

Leading Implant Manufacturers

- Fraunhofer Institute for Biomedical Engineering
- GKSS Center for Biomaterial Development
- Cottbus Technical University
- aap
- Aristotech
- B. Braun Melsungen Aesculap
- Berlin Heart
- Biomet
- Biotronik
- Christoph Miethke

Leading Companies in Regenerative Medicine

- Merete Medical
- OHST Medizintechnik
- Otto Bock Science Center for Medical Technology
- Autotissue
- Co.don
- Epiontis
- ProBioGen
- Transtissue
- Vasotissue
- Zellwerk

Merete Medical – Orthopedic Implants for the Global Market

30 percent of turnover generated abroad

The core expertise of Merete Medical lies in developing and producing implants and instruments for orthopedics and bone surgery. "We produce implants made of metal, absorbable and non-absorbable plastic, bone replacement materials and, in addition, the required instruments," explains Emmanuel Anapliotis, managing director of Merete Medical. The products manufactured by this company, which was founded in 1996, are in much demand across the globe. Roughly 30 percent of the company's turnover is generated abroad from clients in over 40 countries. "The U.S., in particular, is an important market for us," Anapliotis notes. "There, we already have six FDA-approved product accreditations. Together with the renowned Mayo Clinic in Rochester, Minnesota, we've created a new implant for foot surgery." With its subsidiaries in the U.S. and Poland, Merete employs a combined workforce of 105 people. At its headquarters in Berlin-Lankwitz, which is home to roughly 80 employees, Merete conducts research and development and also houses the company's certified production facilities.

"We profit from the region's distinguished expertise."


When working on developing innovative products, Merete takes advantage of the Berlin-Brandenburg region's specific expertise. Important cooperation partners are the Federal Institute for Materials Research and Testing (BAM), the Free University of Berlin (FU), the Technical University of Berlin (TU) and the Fraunhofer Institute for Applied Polymer Research. "We profit from the region's distinguished expertise," notes Anapliotis. "For example, we're currently working with BAM on developing a more bone-friendly surface for hip prostheses that also encourages growth and enables better in-growth of the implant without requiring the use of bone cement." As a result of its innovative work, the company became one of the winners of the "Germany – Land of Ideas" initiative.



Emmanuel Anapliotis
Managing Director, Merete Medical GmbH
www.merete.de

In order to ensure the highest quality, the company forges instead of casting the implants, which are exposed to high amounts of stress. This is a unique field that requires specific knowledge. Merete's implants are forged in the high-tech facilities of Aristotech, a company based in Luckenwalde, Brandenburg. Then, at its own production facilities in Berlin, the final products are made using the forged moulds. Specific expertise is a must for all employees: "Highly qualified experts are the very foundation of Merete's success, and we recruit almost all of them from Berlin and Brandenburg."

"Highly qualified experts are the very foundation of Merete's success, and we recruit almost all of them from Berlin and Brandenburg."





From left to right
Hydrocephalus valve from Christoph Miethke, Potsdam
Orthopedic implants from Merete Medical produced in Berlin and at Aristotech in Luckenwalde
Fibroblasts cultivated in an open-cell foam structure, GKSS Center for Biomaterial Development, Teltow

Life Sciences Cluster Berlin-Brandenburg


Select locations

-  Hospitals
-  Life Sciences Companies
-  Pharmaceutical Companies
-  Research Institutes
-  Universities and Colleges





Berlin Heart®	bernafon ® Innovative Hearing Solutions	BIOMET®	BIOTRONIK excellence for life	B • R • A • H • M • S	B BRAUN SHARING EXPERTISE		
GLOBAL HEALTH CARE	GLUCOMETRIX ®	GLYCOTYPE The GlycoEngineering Company	HBS	hc Berlin Pharma AG the healthcare company	HEALTHWAYS	jpt Innovative Peptide Solutions	
MGB	MOLOGEN AG	NOXXON IPHARMA AG	NYCOMED	<i>Otto Bock</i> ® QUALITY FOR LIFE	PAREXEL ® Expertise that makes the Difference™	Pfizer	PHILIPS
SILENCE THERAPEUTICS	SOMATEX ® Medical Technologies GmbH	VAMED health. care. vitality.	VANGUARD Leading to Technological Excellence	vasotissue	XION medical		



Scienion, a producer of innovative chip technology, is a member of the DiagnostikNet-BB Network

Networks Accelerate Technology Transfer

Intense collaboration between science, hospitals and industry

The unique and high-level density of outstanding facilities and cutting-edge research in the Berlin-Brandenburg region makes it one of the world's leading locations for the life sciences. A key factor in the region's ongoing international success is the intense linkage and cooperation between partners working in scientific research, hospitals, clinics, business and industry. At the interface between science and business, two major regional initiatives – BioTOP Berlin-Brandenburg and TSBmedici – support a wide spectrum of networking and technology transfer in their

respective fields of biotechnology and medical technology. As a result of their excellent work, regional networks receive major financial support from Germany's federal government. Local medical and scientific expertise is also in high demand in networks in Germany and abroad. For example, the region plays a leading role in the NGFN-Plus National Genome Research Network, in the FORSYS systems biology programs and in medical imaging, such as with the Neurocure consortium.

Biotech Networks

- BioHyTec Biohybrid Technologies Network
- Bioresponse – Network for Multi-parameter Analytics
- DiagnostikNet BB
- Genome Analysis in Biological Plant Physiology (GABI)
- Berlin-Brandenburg Network for Drug Discovery and Development (NetDDD)
- Network for RNA Technologies (RiNA)
- Berlin-Brandenburg Glycobiotechnology Network
- Berlin-Brandenburg Nutrigenomics Network
- White Biotechnology Network
- Regenerative Medicine Initiative Berlin (RMIB)
- Ultra Structure Network (USN)
- Center for Molecular Diagnostics and Bioanalytics

Medtech Networks

- Berlin NeuroImaging Center (BNIC)
- Bernstein Center for Computational Neuroscience
- Experimental and Clinical Research Center
- Imaging Network Berlin
- Berlin and Brandenburg Optical Technologies Network (OpTecBB)
- Berlin-Brandenburg Medical Engineering Network (medtecnet-BB)
- Musculoskeletal Research Center Berlin (MRCB)
- Network for Integrated Telemedical Systems (NEST)
- NeuroCure – New Perspectives in Therapies for Neurological Disorders
- Brandenburg Telemed Initiative

The Berlin-Brandenburg Advantage – Strong Network Synergies

Bringing together expertise from a wide array of scientific fields

Experts in Berlin-Brandenburg were quick to notice the tremendous potential for strong synergies that would result from the close linkage of regional players, and they encouraged these developments from the very beginning. “Nowhere else in Europe will you see such outstanding research and intense collaboration between business and science,” explains Dr. Kai Bindseil, director of BioTOP Berlin-Brandenburg. “In the field of biotechnology, Berlin’s 12 networks of expertise ensure that the capital region maintains its prominent international reputation as a leader in fields such as RNA technology, molecular diagnostics and regenerative medicine.” Here, research findings from different fields of expertise are coordinated in an optimal manner. For example, scientific results in the fields of functional genome research on humans, animals, plants and microorganisms are brought together with proteomics, glycobiology and the latest findings in ultra-structure research.

“Nowhere else in Europe will you see such outstanding research and intense collaboration between business and science.”

Strong network linkages are encouraged even further, as Bindseil explains: “These networks are now in the process of expanding to include translational development centers designed to allow the quick and coordinated conversion of research findings into clinical practice and product development. Examples include the Berlin-Brandenburg Center for Regenerative Therapies, the Center for Molecular Diagnostics and Bioanalytics and the Experimental and Clinical Research Center (ECRC), a cooperation between the MDC and the Charité hospital.” Bindseil is confident that: “In the game of international biotech research and production, the capital region holds a hand full of trump cards.”



Dr. Helmut Kunze
Director, TSB Medici
www.tsbmedici.de

Dr. Kai Bindseil
Director, BioTOP
www.biotop.de

The same applies in equal measure to medical technology. The two branches engage in increasing cooperation in Berlin-Brandenburg, for example, in the complex fields of biohybrid technologies, regenerative medicine and new imaging techniques. The Berlin Imaging Network, which is coordinated by TSB Medici and has 12 partners drawn from science and business, helps coordinate work in the field of diagnostic imaging ranging from molecular imaging to the ongoing development of instrument engineering, including computer tomography, magnetic resonance tomography and other optical procedures. Close connections to biotechnology exist in the fields of contrast-agent research and the development of new nanoparticles.


“We focus on networking expertise in the fields of biotech and medical technology.”

Dr. Helmut Kunze, director of TSB Medici, explains: “We focus on networking expertise in the fields of biotech and medical technology as it is available in the region with partners from science, hospitals, manufacturers of large medical devices and among small and medium-sized companies.” Technology-oriented networks, such as the OpTecBB optical technologies network, integrate different key technologies in developing innovative products. The goal of medtecnet, a Berlin-Brandenburg suppliers’ network, is to forge closer links between medical technology companies and the purchasers of their products.



From left to right

The White Biotechnology Network is one of the organizations coordinated from the Luckenwalde Biotech Park
The lab for medical genome research in Berlin-Buch Ludwig Erhard Haus in Berlin-Charlottenburg, home of Berlin Partner, BioTOP Berlin-Brandenburg and TSB Medici



Berlin – Headquarters and research facilities of Bayer Schering Pharma

Innovative Pharmaceutical Location

Successful and versatile from medium-sized companies to global players

The ongoing success of pharmaceutical companies based in Berlin and Brandenburg derives from the long history of innovative products and a strong medical tradition that dates back to the 19th century. The pharmaceutical industry profits from the region's outstanding scientific landscape, its clinical-research environment and its close proximity to decision-makers in the health care field. These factors apply to global players such as Bayer Schering Pharma, Pfizer, Berlin-Chemie (Menarini Group), Nycomed and sanofi-aventis, but also in equal measure to the region's 25 medium-size pharmaceutical companies. The excellent

conditions found in Berlin-Brandenburg also attract companies from abroad. For example, sanofi-aventis conducts its marketing activities, sales and distribution for Germany from offices in Berlin. Nycomed is a center of expertise in solid-form medication that operates a state-of-the-art facility in Oranienburg for manufacturing over 80 products. In 2009 and 2010, roughly €20 million will be invested in further expanding these production facilities. Yet another recent example of the region's pull is Shire's decision to concentrate its German activities in Berlin.

Global Players in the Region

- Bayer Schering Pharma
- Berlin-Chemie (Menarini Group)
- Nycomed
- Pfizer
- sanofi-aventis
- Shire

Successful Medium-sized Pharmaceutical Companies in the Region

- Advance Pharma
- ALPHAMADE
- Bausch & Lomb Dr Mann Pharma
- CT Arzneimittel
- Dentinox
- Dr. Kade Pharmazeutische Fabrik
- Haupt Pharma
- Heyl chemisch pharmazeutische Fabrik
- Intendis
- Klosterfrau Berlin
- medphano Arzneimittel
- MUCOS Pharma
- OcuLentis
- Schöning Pharmazeutische Präparate
- Spreewälder Arzneimittel
- Steiner & Co. Deutsche Arzneimittelgesellschaft
- Steripharm Pharmazeutische Produkte

Bayer Schering Pharma – A Global Player at Home in Berlin

Leading position in specialty pharmaceuticals

Bayer Schering Pharma is a globally active pharmaceutical company headquartered in Berlin. On an international scale, it ranks among the top 10 specialty pharmaceutical companies in the world. "We focus on four fields in which we contribute significantly to medical progress," explains Andreas Fibig, CEO of Bayer Schering Pharma AG. "These are Diagnostic Imaging, General Medicine, Specialty Medicine and Women's Healthcare."

"Berlin is the site of our headquarters – and it's also one of our foremost research locations."

The world leader in the field of hormonal contraception also occupies leading market positions in the field of contrast agents, multiple sclerosis therapy and hematology. The company is also a strong partner in the fields of cardiology and oncology. In addition to so-called "small molecules," Bayer Schering Pharma also concentrates on developing products manufactured using biotechnology. "Berlin is the site of our headquarters – and it's also one of our foremost research locations," Fibig emphasizes. "Our activities here cover the entire value chain from research in the fields of oncology, women's health care and diagnostic imaging, all the way to development and production." Marketing for the company's globally successful products is also managed from Berlin. Over 5,000 people are employed here at the largest site of this globally active company.

Berlin proves its worth as a business location: "Berlin has a very good research and hospital environment, and it also has so many other factors that make it an attractive place," Fibig notes. "Our goal is to grow stronger than the market, and we can only achieve this if we have a committed and qualified workforce, the right partners, a productive landscape and the corresponding infrastructure. Berlin has it all."

Science for a better life

In keeping with the company's motto, "Science for a better life," Bayer Schering Pharma focuses on researching and developing innovative medicine and new therapeutic approaches in fields where, despite considerable advances, further innovation is still necessary. The company thus invests 15 percent to 17 percent of annual sales into R&D activities.

An important aspect of the company's corporate strategy involves cooperating with external partners from academic institutions, hospitals and companies. "Our global network allows us to jointly contribute to the improvement of therapies in a successfully and sustainable manner," Fibig argues. Bayer Schering Pharma is very well-connected in the capital region as well. In fact, there are a number of points of contact for further activities, whether it be cooperative efforts with regional universities and colleges, research institutes and biotech companies, its work with the Charité hospital in research and clinical studies, or the proximity to health care policy decision-makers.



Andreas Fibig
CEO Bayer Schering Pharma AG
www.bayerscheringpharma.de



From left to right
Nycomed Oranienburg, central production facility for solid-form medication
Bayer Schering Pharma in Berlin-Wedding
Pfizer Germany headquarters in Berlin-Mitte



A microbiology lab at the Helios Clinic

Excellent Clinical Research and Health Care

State-of-the-art medical research and health care

The Berlin-Brandenburg region is home to one of Europe's largest university hospitals, Charité – University Medicine Berlin, and possesses many other essential advantages, including a tremendous concentration of 120 hospitals and specialized clinics, a broad level of outstanding basic research, a high degree of advanced medical care, specialized expertise in individual medical fields and ideal conditions for clinical research. The Vivantes Health Network, which represents the largest municipal hospital corporation in Germany, is headquartered in Berlin. The privately held

Helios Group, which belongs to the Fresenius SE health care corporation, also has its central offices in Berlin. Other hospital and clinic operators active in the region are the DRK Hospitals Berlin and the association for the construction of hospitals supported by Germany's Protestant Church. Leading contract research organizations also take regular advantage of the large pool of patients in the region. Parexel International, for example, currently has a workforce of over 1,500 employees.

Charité – University Medicine Berlin*

Berlin sites	4	Students	7,325
Charité centers	17	Graduate research groups	4
Clinics and institutes	107	German Research Foundation (DFG) research groups	5
In-patients/year	130,200	Specialized research fields	15
Out-patients/year	497,000	New studies/year	543
Full-time employees	10,400	Spin-offs	20
Annual turnover in € billion	1.1	Third-party funds/year in € million	117

*Acc. to its 2007 annual report

Vivantes Health Network*

Beds	5,217
In-patient cases	189,279
Out-patient cases	265,431
Number of employees	13,134
Annual turnover in € million	727
Annual profits in € million	2.1

*Acc. to its 2007 business report

Traditionally Cutting-edge: Charité – University Medicine Berlin

Professor Einhäupl, in 2010, Charité will celebrate its 300th anniversary. How would you rank the hospital today on an international scale?

Charité is one of the most important university hospitals in Europe. We perform excellent research and teaching and offer cutting-edge medical care in a patient-friendly manner. Our goal is to be caring, innovative and entrepreneurial and also to set standards for medicine in Germany. On an international scale, Charité is one of the most recognized hospitals in the world next to Johns Hopkins University in Baltimore and Harvard. This is due, in part, to our strong tradition, in particular our achievements over the last century, but it is also evidence of Charité's ability to emerge once again, after the fall of the Berlin Wall, as a leading university hospital in Europe.

What role does Charité play in terms of business and industry?

Charité plays a very important role in the regional economy. We employ roughly 14,000 people and have initiated diverse activities designed to promote entrepreneurial efforts. At the same time, Charité is the major generator of the health care industry in Berlin-Brandenburg. Wherever high-quality science is done, businesses are always soon to follow. The growing number of life-science companies is evidence of how successfully Berlin-Brandenburg is developing in this respect, in addition to the increasing relocation of major pharmaceutical companies in Berlin. These developments give us a competitive advantage over other locations. We have partnerships with almost all major research-based pharmaceutical companies in clinical studies and we jointly operate the Imaging Science Institute (ISI) with Siemens.

“Charité is the major generator of the health care industry in Berlin-Brandenburg.”



Prof. Dr. Karl Max Einhäupl
CEO of Charité – University Medicine Berlin
www.charite.de

“Our cooperation with industry covers the entire spectrum of value creation.”

What shape do your cooperative efforts with other regional institutes assume?

We work very successfully on a project level with several hospital operators in the region. Our future cooperation with Vivantes – which is, like us, publically owned – is set to go even further. We're looking to intensify our cooperation in a series of steps, starting with the mutually beneficial integration of administrative functions, for example, in the field of purchasing. Our next step is to merge and jointly operate our service activities, in particular our laboratory work. We're already hard at work preparing for an optimal transition in both fields. Our third step takes us to clinical cooperation, which will, no doubt, be much more difficult as it involves a high degree of complexity.

We also plan to intensify our existing cooperation with non-university research institutions, such as the Helmholtz-, Max-Planck- and Leibniz institutes. For example, together with the Max Delbrück Center, we plan to erect a new building for the Experimental & Clinical Research Center (ECRC) in Berlin-Buch and an Institute for Medical Systems Biology at the Charité Campus Berlin-Mitte.



From left to right

The Vivantes Auguste Viktoria Clinic, one of nine locations of the Vivantes Health Network in Berlin

Main entrance of Potsdam's Ernst von Bergmann Clinic with its emergency center

Tomotherapy system at the Charité's clinics for therapeutic radiology



At its facilities in Oranienburg, Nycomed produces more than 80 products in solid medication forms

Ideal Conditions for Manufacturing

Internationally competitive location, well-educated technical personnel

For the chemical-pharmaceutical, industrial medicine and biotechnology sectors, Berlin-Brandenburg is a very attractive production location for a number of reasons, including its large pool of educated professionals, its unique and investor-friendly cooperation with public authorities and the best subsidy opportunities available in Europe. For example, global players, such as Nycomed and BASF, manufacture pharmaceuticals, plastics and crop-protection products at state-of-the-art facilities in Brandenburg. Well-known pharmaceutical companies, such as Bayer Schering

Pharma and Berlin-Chemie, also have a long tradition of production in Berlin alongside global medical engineering companies, such as Biotronik. Several small and medium-sized businesses in the fields of medical engineering and biotechnology cover the entire value chain all the way up to production. The product range is broad and varies from diagnostics, medications and vaccines to pacemakers, implants and devices designed to be used in minimally invasive surgery.

Local Production Companies

- BASF
- Bausch & Lomb Dr. Mann Pharma
- Bavarian Nordic
- Bayer Schering Pharma
- B-Braun Melsungen
- Berlin-Chemie (Menarini Group)
- Biotronik
- BRAHMS
- Eckert & Ziegler

- Gelkaps
- Merete Medical
- MGB
- Nycomed
- OHST
- Vanguard

Ideal Conditions for Production

- Highly educated technical personnel
- Attractive financial investment support (EU Target 1 and Target 2 areas)
- Favorable labor costs
- Professional assistance in setting up businesses in the region
- Rapid-conversion business ventures
- Political support

Schwarzheide – BASF's Third Largest Production Facility in the World

Dr. Tebel, BASF has been in Schwarzheide since 1990. What made you choose this location ?

The decisive factor was the polyurethane chemistry that already existed here. These were business contacts that had been in place since before the Wall fell. We also used the opportunity to develop and expand facilities in the states of the former East Germany. Plus, Schwarzheide is perfectly positioned as a gateway to Eastern European markets.

How would you rate Brandenburg today as a production location on an international scale ?

The region offers us clear advantages over other European locations. We regularly measure the cost efficiency of our production sites using an internal company benchmarking process, and the accomplishments of our Brandenburg facility have won us a leading position in Europe. The main arguments in favor of the Berlin-Brandenburg region are its low-cost environment and its pool of highly educated professionals.

“Schwarzheide is perfectly positioned as a gateway to Eastern European markets.”

What markets does BASF's Schwarzheide facility service ?

We have a very clear concept within the BASF group. In principle, we produce where the market is. In 2006, Schwarzheide began producing a biodegradable plastic we call Ecoflex – a product development with great potential. Ecoflex is the basic material of Ecovio, a plastic based on renewable resources (PLA). In 2008, we also began expanding our production of the active plant-protection agent F500. Our long-term goal with this investment is to double our production capacity of this new-generation strobilurin-based defense substance.

“The accomplishments of our Brandenburg facility have won us a leading position in Europe.”


Ecoflex is processed directly on the premises. How have your experiences been when it comes to bringing new middle-size partners to the region ?

Our cooperation with the Brandenburg Economic Development Board (ZAB), the regional business development agency, is very good. It's one of the definite strengths of the 15 business relocation projects we've successfully undertaken here. We've enjoyed excellent investment support, good contact coordination and close relationships to public authorities, and these are all definitely major arguments in favor of Schwarzheide. All the companies that have decided to set up offices in the region are more than happy with the support they've received.

Two further examples from the field of industrial biotechnology are BIOPETROL Schwarzheide GmbH and BIOPolymer Technologies, both of which process Ecoflex. Yet another decisive factor in favor of Schwarzheide as a production location is the fact that things get done faster here than in other German federal states. New businesses like these help to expand the value chain and create advantages for everyone involved.




Dr. Karl Heinz Tebel
CEO, BASF Schwarzheide GmbH
www.basf-schwarzheide.de



From left to right
BASF large-scale production facility in Schwarzheide
Endoscopic optics and complete systems for minimally invasive surgery produced by MGB Endoskopische Geräte in Berlin
Production at Berlin-Chemie in Berlin-Adlershof

STRATEGIC ADVANTAGES



Quick links to the entire world: The new Berlin Brandenburg International Airport (BBI)

Berlin-Brandenburg: Ready for Takeoff

Berlin-Brandenburg International, the new hub starting in 2011

The new Berlin-Brandenburg International Airport (BBI) will enter into operation in October 2011. Europe's most modern airport will offer connections to roughly 160 destinations in over 50 countries with an initial capacity of 22 million to 25 million passengers. The new, high-tech airport in the capital region will offer companies and business people alike ideal global and regional connections and will have its own train station directly under the terminal. The rail airport-shuttle will take roughly 20 minutes

to arrive in the center of Berlin, and the adjacent autobahn will also enable quick transit in all directions within the capital region. Commercial space is available for investors in the direct vicinity of the airport, including at the BBI Airport City and the BBI Business Park Berlin, the largest industrial park in the capital, as well as at a number of other interesting commercial centers and locations along the autobahn.



Dr. Reinhard Uppenkamp
CEO Berlin-Chemie AG
www.berlin-chemie.de

Gateway between East and West

"Berlin-Chemie in Berlin-Adlershof is one of the fastest-growing companies in the research-based pharmaceutical industry in Germany. We obtain more than half of our sales in Eastern Europe. Berlin is a gateway between East and West, which makes it an ideal location for the ongoing positive development of Berlin-Chemie AG.

Over the past 10 years, we've been able to increase our sales by a factor of 10 and enlarge our number of employees both at home and abroad by 2,950 to over 4,570."

Strategic Advantages in Berlin-Brandenburg

More value for your investment

Berlin-Brandenburg offers investors the best financial support available in Europe. Investment subsidies are granted in the form of direct payments. The support programs created for these measures combine funds from the EU, Germany's federal government and the states of Berlin and Brandenburg. Large companies in the capital region receive investment subsidies of up to 30 percent, medium-size companies up to 40 percent, and small companies up to 50 percent. R&D projects are also supported effectively via attractive programs at the state and federal levels. Investors receive additional support in the form of programs set up by the German government to encourage growth in the states of the former East Germany.

"LGC is Europe's leading provider of analytical services. We are active in the fields of reference materials, forensics, chemistry, food chemistry and biochemistry. After several other investments in Europe, we invested in facilities in Luckenwalde, near Berlin, which marked the establishment of our first laboratories outside of England. We continue to be very impressed by the optimal conditions found in the capital region. In particular, we have been encouraged to make further investments in Berlin and Brandenburg as a result of the availability of state-of-the-art laboratory facilities and highly qualified employees at internationally competitive rates. We also benefit from the region's tailor-made offerings of financial support programs."



Uwe de Buhr
Non-Executive Director LGC Ltd.
www.lgc.co.uk

fDi
European Cities
of the Future
2008/09

Top 50
BERLIN,
GERMANY

Highly qualified employees

The region has a workforce with an above-average level of highly educated, multilingual and multicultural employees who provide a benefit to companies based in the region. They are also the reason why Berlin recently won yet another award, namely a top-10 position in the "European City of the Future – Germany 2008/9" competition. Each year, the British magazine Foreign Direct Investment of

the Financial Times Group honors regions and cities with the best prospects for success for foreign investors. Berlin's high-level workforce qualifications, its education levels, availability of multilingual employees and its total expenditures on education were taken as proof of the city's attractiveness.

Optimal infrastructure for setting up businesses

Berlin-Brandenburg is well-known for providing a wealth of affordable and available office, laboratory and industrial space. The region offers roughly 1,000,000 m² of state-of-the-art laboratory space in a network of science and technology parks. Companies profit from the high-level concentration of internationally renowned research institutes, universities, hospitals and clinics as well as the proximity to international corporations, service providers and associations in the life sciences. Real estate and the cost of living and renting lie considerably under those of other major metropolitan regions.

"For years now, metanomics has taken advantage of the region's outstanding R&D opportunities and its internationally unique scientific and technological environment. We've enjoyed great success in joint projects with several scientific institutions, such as the Charité hospital's various clinics and with numerous companies."



Dr. Arno Krotzky
CEO metanomics GmbH and
metanomics Health GmbH
www.metanomics.de
www.metanomics-health.de




Recreation and relaxation at your doorstep: Berlin-Brandenburg boasts Europe's largest group of interconnected rivers and lakes

A Great Place to Live

Cultural metropolis and pure nature

The capital region offers a wonderful mixture of urban lifestyle, culture, history and a beautiful natural environment. The city of Berlin continues to exert a magnetic attraction on young and creative people, but there are also plenty of calm and quiet neighborhoods and much open space for recreation and relaxation. Potsdam, the state capital of Brandenburg, lies just outside the Berlin metropolitan area and combines the delightful charm of historical Prussian parks and gardens with modern city living and sophisticated residential housing at water's edge. The region's many historical locations, parks and natural environments offer an ideal setting for recreational activities of all kind, and they are all located at the very heart of Europe's largest connected set of rivers and lakes.

This range of urban and rural landscapes makes the region a great place to live for all lifestyles. Openness and tolerance characterize life in the region. People from more than 185 nations call Berlin-Brandenburg home and enrich the culture and lifestyle of the region. Many new Berliners and Brandenburgers, as well as visitors from all over Germany and abroad, continue to be pleasantly surprised by the region's affordable cost of living. Whether for rental and real estate prices, cultural opportunities or recreational activities – the price level is clearly well below that of other Western metropolitan areas.





Investing Made Easy

The region's two business development agencies, Berlin Partner GmbH and the Brandenburg Economic Development Board (ZAB), are the key contact partners for companies in Berlin and Brandenburg. They provide comprehensive support over the course of your company's relocation in the region – professional, quick, with no red tape and free of charge.

- **Business Location** Facts and figures on the life science industry and the Berlin-Brandenburg economic region www.businesslocationcenter.de/lifesciences
- **Real Estate and Facilities** Assistance in locating properties and sites for sale or rental
- **Financial Support and Subsidies** Expert advice on subsidies and financing opportunities
- **Qualified Personnel** Support in recruiting and training new staff
- **Contacts** to government agencies, banks, chambers of commerce, associations and business networks

Berlin Partner GmbH

Ludwig Erhard Haus | Fasanenstrasse 85 | 10623 Berlin

Contact: Carolin Clement

Team Director Life Sciences

T: +49 30 39980-230 | F: +49 30 39980-239

carolin.clement@berlin-partner.de

www.berlin-partner.de



Brandenburg Economic
Development Board

Brandenburg Economic Development Board (ZAB)

Steinstrasse 104–106 | 14480 Potsdam

Contact: Dr. Andreas Pachten

Team Director Life Sciences

T: +49 331 660-3838 | F: +49 331 660-3829

andreas.pachten@zab-brandenburg.de

www.invest-in-brandenburg.com



BioTOP Berlin-Brandenburg

The BioTOP Network supports companies in the fields of biotechnology, biomedicine and pharmaceuticals at the interface between science and business. BioTOP is your major contact partner for all matters relating to the biotech industry in the German capital region.

BioTOP Berlin-Brandenburg

Fasanenstrasse 85 | 10623 Berlin

Contact: Dr. Kai Bindseil | Director

T: +49 30 318622-11, F: +49 30 318622-22

biotop@biotop.de | www.biotop.de



TSB Medici Berlin

TSB Medici is an initiative of the Berlin Technology Foundation and is responsible for the region's development as a national center of expertise in the fields of medicine and medical technology. It brings together scientific research institutions, hospitals, business and industry and also hosts individual network projects.

TSB Medici

Fasanenstrasse 85 | 10623 Berlin

Contact: Dr. Helmut Kunze | Director

T: +49 30 46302-547 | F: +49 30 46302-444

kunze@tsbmedici.de | www.tsbmedici.de



Berlin-Brandenburg Health Care Industry Network

The Berlin-Brandenburg Health Care Industry Network – with its “HealthCapital Berlin-Brandenburg” umbrella brand – is responsible for coordinating the implementation of the region's health care master plan. The network brings together players from the fields of business, science and maintenance and promotes the further development of the regional health care cluster.

Berlin-Brandenburg Health Care Industry Network

HealthCapital Berlin-Brandenburg

Potsdamer Strasse 86 | 10785 Berlin

Contact: Raphael Krüger | Network Coordinator

T: +49 30 206198-52 | F: +49 30 202148-02

info@healthcapital.de | www.healthcapital.de

IMPRINT



Publisher

Berlin Partner GmbH

Ludwig Erhard Haus | Fasanenstrasse 85 | 10623 Berlin

T: +49 30 20240-0, F: +49 30 20240-166

info@berlin-partner.de

www.berlin-partner.de

In cooperation with:

Brandenburg Economic Development Board (ZAB),

BioTOP Berlin-Brandenburg and TSB Medici

Commissioned by:

Berlin Senate Department for Economics, Technology and Women's Issues and the Brandenburg State Ministry of Economics

Content, Text

Almut Gebhard,
Strategische Kommunikation, Berlin

English Translation

The Hagedorn Group
www.hagedorn-group.com

Design

Fuenfwerken Design AG Berlin
www.fuenfwerken.com

Photography

Matthias Fischer, mfisher@macht.de
(except for the following):

© Acri.Tech GmbH: p.10 | © BASF Schwarzheide GmbH: p.21 left, | © Bayer Schering Pharma AG: p.2, p.5 right, p.9 middle, p.16, p.17 portrait, p.17 middle | © B. Braun Melsungen AG: p.7 right | © Berlin Airports: p.22 above | © Berlin-Chemie AG: p.21 right | © Berlin Heart GmbH: p.7 left | © Berlin Partner GmbH/diephotodesigner.de: p.3 right | © Berlin Partner GmbH/Scholvien: p.1 | © Biotechnologiepark Luckenwalde GmbH: p.15 left | © Biotronik GmbH & Co. KG: p.6, p.7 portrait | © B.R.A.H.M.S AG: p.7 middle, p.9 right | © Charité Universitäts Medizin Berlin: p.19 right | © Christoph Miethke GmbH & Co. KG: p.11 left | © Celon AG: p.5 middle | © Eckert & Ziegler Strahlen- und

Medizintechnik AG: p.4, p.5 left | © Epigenomics AG: p.9 left | © Klinikum Ernst von Bergmann GmbH: p.19 middle | © Fraunhofer Institute for Biomedical Engineering (IBMT): p.3 left | © GKSS Research Center Geesthacht GmbH: p.11 right | © Helios Kliniken GmbH: p.18 | © Max Delbrück Center for Molecular Medicine (MDC)/Uwe Eising: p.15 middle | © Merete Medical GmbH: p.11 middle | © Metanomics GmbH: p.3 middle | © MGB Endoskopische Geräte GmbH Berlin: p.21 middle | © Nycomed Oranienburg GmbH: p.17 left, p.20 | © Pfizer Deutschland GmbH: p.5 portrait, p.17 right | © Scienion AG: p.14 | © TMB-Fotoarchiv/Thum: p.24 | © TSB Technology Found-

ation Berlin Group/Eißrig: p.8 | © Vivantes Netzwerk für Gesundheit GmbH: p.19 left.

Production

M8 Labor für Gestaltung, Berlin
www.macht.de

The companies presented here were selected to serve as examples. They are in no way meant to represent a comprehensive listing.

The information contained herein is provided without liability and is subject to change.

© 2nd, revised edition – April 2009

